AC Immune/$ACIU

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Ticker

$ACIU
Sector
Primary listing

Employees

153

Headquarters

Lausanne, Switzerland

AC Immune Metrics

BasicAdvanced
$351M
-
-$0.63
1.65
-

What the Analysts think about AC Immune

Analyst ratings (Buy, Hold, Sell) for AC Immune stock.

Bulls say / Bears say

Interim results from the Phase 2 VacSYn trial of anti-alpha-synuclein immunotherapy ACI-7104.056 showed strong immunogenicity and a favorable safety profile in early Parkinson’s patients, reinforcing its best-in-class potential (AC Immune Q2 Press Release).
The small molecule NLRP3 inhibitor program (ACI-19764) has entered IND-enabling studies, diversifying the pipeline and creating an early-stage value inflection opportunity (AC Immune Q2 Press Release).
A strategic review and operational efficiencies have extended the company’s cash runway to the end of Q3 2027 with CHF 127.1 million in resources, ensuring funding into major upcoming clinical milestones (AC Immune Strategic Review Release).
Operational restructuring cuts around 30% of AC Immune’s workforce, potentially disrupting project continuity and delaying development timelines (AC Immune Strategic Review Release).
The ABATE Phase 2 trial of anti-Abeta vaccine ACI-24.060 only reaches the 12-month treatment mark for its third Alzheimer’s cohort in December 2025, postponing interim data until early 2026 (AC Immune Q2 Press Release).
Cash runway projections to Q1 2027 exclude any potential milestone payments, leaving AC Immune’s liquidity contingent on achieving uncertain clinical and partnering milestones (AC Immune Q2 Press Release).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.

AC Immune Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AC Immune Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACIU

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs